Hemostemix (CVE:HEM) Stock Price Up 30% – Time to Buy?

Hemostemix Inc. (CVE:HEM)’s stock price rose 30% on Wednesday . The company traded as high as C$0.15 and last traded at C$0.13. Approximately 430,289 shares changed hands during mid-day trading, a decline of 10% from the average daily volume of 480,285 shares. The stock had previously closed at C$0.10.

Hemostemix Stock Up 30.0%

The business has a 50-day simple moving average of C$0.10 and a two-hundred day simple moving average of C$0.14. The stock has a market capitalization of C$18.94 million, a P/E ratio of -3.79 and a beta of 0.20. The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07.

Insider Transactions at Hemostemix

In other Hemostemix news, Director Peter Alan Lacey bought 200,000 shares of the firm’s stock in a transaction dated Thursday, March 6th. The shares were bought at an average price of C$0.15 per share, for a total transaction of C$30,000.00. Company insiders own 10.43% of the company’s stock.

Hemostemix Company Profile

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.